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Parvovirus B19 is the exclusive human pathogen of the Erythrovirus genus. In classical view, the B19 DNA sequence shows
little variability, with no disease-specific or tissue type specific associations. We examined skin biopsies from patients with
B19-unrelated skin disease or from constitutionally healthy adults by polymerase chain reaction assays for four different
genomic regions of the B19 virus. Sequencing showed that the skin-derived viral DNA differed within the protein-coding
region from the B19 reference sequences by 10.8% and from the V9 variant by 8.6% and within the noncoding region (covering
nucleotides 189–435 of the promoter region) by 26.5 and 17.2%, respectively. Despite this sequence difference, the promoter
region was shown by a luciferase gene expression assay to be biologically active. We have detected a new B19 virus
genotype, K71, which differs extensively from the known B19-virus genotypes and is persistently carried in human skin.; persiIntroduction. Human parvovirus B19, member of the
Erythrovirus genus, is a small DNA virus causing a vari-
ety of diseases in humans. Its prevalent manifestations
include erythema infectiosum (“fifth disease”) of children
and young adults and acute or chronic arthropathies
symptomatic especially among females. The virus is the
major etiologic agent of aplastic crisis complicating he-
molytic anemias of various forms. During pregnancy, B19
can be transmitted from mother to fetus, not infrequently
leading to hydrops and fetal death. The host cells for B19
replication in bone marrow are erythrocyte precursors
CFU-E and BFU-E (1, 2). Putative mechanisms for the
restricted cell tropism include block in transcript matu-
ration based on RNA splicing (3) and regulation of the P6
promoter by erythroid-specific intracellular factors (4). In
general, the genomic sequence of this virus has shown
little variability (5), and no disease-specific genotypes
have been described. However, in 1998 a new B19 vari-
ant V9 was found (6), which differed by more than 10%
from the previously reported B19 genotypes.
We and others have shown ubiquitous long-term per-
sistence of B19 DNA in synovial tissue (7–10); in bone
marrow such persistence appears to be less prevalent
(11–13). In skin, B19 DNA was first detected in a patient
with erythema infectiosum (14), and subsequently also in© 2002 Elsevier Science (USA)
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224nonsymptomatic subjects with long-term B19 immunity
(15). While the B19 genome persistence has important
diagnostic implications (16), its molecular and cellular
mechanism is unknown. As we have shown using PCRs
for the NS1, VP1, and VP2 genes (17), the viral coding
region persists in synovium as a continuous, intact DNA
molecule, 99% identical in sequence with the blood-
derived B19 reference Au (18). By contrast in skin only the
VP1 region gave positive polymerase chain reaction
(PCR) results consistently, whereas the other B19
genomic regions amplified poorly. Here, we describe the
molecular characteristics of the parvoviral DNA persist-
ing in skin and present therein a novel B19 genotype
termed K71.
Results. Skin and serum samples were available from
15 B19-seronegative and from 19 B19-seropositive sub-
jects with past immunity (IgG with nonacute epitope-
type specificity and IgM). In skin, all the seronegative
subjects were B19 VP1-DNA negative by PCR, whereas
of the seropositive subjects 14 of 19 (74%) were VP1-DNA
positive. However, among the VP1-positive dermal sam-
ples only 5 of 14 gave the expected positive results in
conventional B19 NS1- and VP2-PCRs (using standard
B19 primers and probes), whereas the remaining 9 of 14
samples showed poorly reproducible amplicons or weak© 2002 Elsevier Science (USA)
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hybridization signals (Fig. 1, Table 1). The weakly hybrid-
izing PCR products from four subjects were sequenced
directly, and two subjects’ DNA preparations underwent
several additional PCRs (see Materials and Methods) for
cloning and sequencing.
From one dermal B19 DNA isolate (LaLi) we se-
quenced nucleotides 144–4763, and from an other
(HaAM) we sequenced nucleotides 144–1510 and 2134–
4763 [numbering according to the Au reference (18)].
Within the coding region, comparison with the B19 Au
reference sequence revealed at the DNA level a diver-
gence of 12.9% within the NS1 sequence, 4.6% within the
VP1-unique sequence, and 11.9% within the VP2 se-
quence (Table 2). At the protein level, the respective
divergences were 6.0% (NS1), 4.4% (VP1-unique), and
1.1% (VP2). As compared with the V9 variant, the respec-
tive sequence differences were 7.6, 8.2, and 10.1%. All in
all the DNA sequences of the two dermal isolates (LaLi
and HaAM) differed from each other by only 0.3%.
Within the noncoding area (nt 189–435, including the
promoter region) the dermal isolate (LaLi) differed from
the Au reference extensively, by 26.5% (Table 2). Within
this region the two reference sequences (Au and Wi)
differ from each other by only 2%. Also a conventional
B19 genotype originating from skin differed from the Au
sequence by only 2.2% (not shown).
Seeking additional evidence of genetic clustering and
abnormal variation of the dermal B19 isolates, the pro-
tein-coding region of the LaLi sequence was aligned
with 13 B19 sequences from GenBank, including the
blood-derived references Au (18) and Wi and four of our
previously published synovial B19 sequences (17), the
variant V9 (19), and a Simian parvovirus (20). A phyloge-
netic tree based on these data was constructed. The B19
isolates from blood and synovial tissue formed a con-
densed cluster except for the two variants K71 and V9
that remained far beyond the B19 group (Fig. 2) and apart
from each other.
To determine whether the K71 promoter, regardless of
its extensive DNA sequence variation, had retained the
ability to induce transcription, the noncoding regions of
B19 and K71 were integrated into a pGL3-Enhancer vec-
tor system (Promega Corp., Madison, WI) containing a
firefly luciferase as a reporter (21). The vectors were
transfected in UT7/Epo-S1 cells, earlier shown suscep-
tible to B19 infection (22). The luciferase gene under
control of a strong SV40 promoter (pGL3-Control) and
mere pGL3 Enhancer were used as positive and nega-
tive controls. The amount of luciferase expressed in cells
transfected by each construct, as compared to positive
and negative controls, was measured. The expressed
luciferase activities (in relative light units, RLU) in the cell
lysates were 28,476 and 29,899 (mean: 29,187.5) for the
conventional B19 genotype, 1466 and 1371 (mean: 1418.5)
FIG. 1. B19-PCR hybridization with four subjects’ skin samples. Each
sample, in three serial dilutions (100; 101; 102), underwent PCR fol-
lowed by hybridization for VP1- (membrane A), NS1- (membrane B), and
VP2-genomic regions (membrane C). Sample “LaP” (lanes 1–3), sample
“BrÅ” (lanes 4–6), and sample “HaP” (lanes 7–9) were positive in VP1
PCR only, whereas sample “SaM” (lanes 10–12) was positive in all three
PCRs.
TABLE 1
Results of B19- and K71-Specific PCRs in Skin from
B19-Seropositive Subjects
B19-PCR
K71-PCR
TotalPositive Negative
VP1 pos 9 5 14
NS1, VP2 pos 0 5 5
NS1, VP2 neg 9 0 9
VP1 neg 0 5 5
Total 9 10 19
Note. Additional samples from B19-seronegative subjects (N  15)
were DNA-negative by all the B19-PCRs.
TABLE 2
Sequence Divergences between the Different B19 Genotypes (the
Conventional B19 Genotype Represented by Isolate Au, the K71
Genotype Represented by Isolate LaLi, and the V9 Genotype)
non-cdsb cdsb NS1 VP1/2 VP2 uVP1
DNAa
LaLi vs Au 26.5 10.8 12.9 9.0 10.9 4.6
LaLi vs V9 17.2 8.6 7.6 9.5 10.1 8.2
V9 vs Au 30.7 12.5 13.4 11.7 13.0 8.5
Au vs Wi 1.6 0.8 0.7 0.9 1 0.6
Protein
LaLi vs Au 6.0 2.1 1.1 4.4
LaLi vs V9 3 2.7 1.3 6.2
V9 vs Au 5.8 3.1 1.4 6.6
Au vs Wi 0.8 0.5 0.4 1.3
a Divergences were obtained by the Distances (with no corrections)
program of the Wisconsin Package of GCG.
b cds stands for the total protein-coding sequence (nucleotides 436–
4789). Non-cds stands for the noncoding sequence (nucleotides 189–
435).
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for the K71 genotype, and 1831 and 1966 (mean: 1898.5)
for the strong positive control SV40. For the negative
control, the corresponding values were 271 and 334
(mean: 302.5). These results showed that in UT7/Epo-S1
cells both the K71 and the B19 promoters were biologi-
cally active.
Finally, all the skin samples (N  34) were studied by
PCR, using NS1-gene primers specific for the new ge-
notype (K71). DNA of K71 was detected in 9/19 B19-
seropositive and in 0/15 B19-seronegative subjects (Fig.
1, Table 1). All in all, among constitutionally healthy B19-
seropositive adults, K71 was more prevalent (47%) than
the conventional B19 genotype (26%). No sample con-
tained both K71 and B19 genotypes. For comparison, 16
synovial tissue samples, previously tested positive by
NS1-, VP1-, and VP2-PCRs for the conventional B19, were
studied using K71-specific primers. All B19-positive sy-
novial samples were K71 negative.
Discussion. Our initial aim was to determine the mo-
lecular characteristics of the B19 virus DNA in human
skin, as in synovial tissue (23). Samples of skin were first
screened for B19 DNA with a nested PCR amplifying a
relatively constant region in the middle of the viral ge-
nome, including the VP1 unique area. Subsequently NS1-
and VP2-PCRs were performed. To our surprise, many
skin samples were positive by the VP1-PCR alone. Se-
quence analysis revealed a novel B19 genotype, K71.
Among constitutionally healthy B19 seropositive adults
(N  19), K71 was more prevalent (47%) in skin than the
conventional B19 genotype (26%).
Comparative analysis by BLAST or FASTA with se-
quences stored in GenBank or EMBL database showed
this new genotype to be B19-related. However, its diver-
gence from all blood-derived sequences of B19 and from
the previously published variant V9 was great. At the
DNA level, the protein-coding sequences differed by
10.8% from the Au isolate and by 8.6% from V9.
In the K71 protein-coding region, no insertions, dele-
tions, or additional stop codons were found. Interestingly,
the gene encoding the NS1 protein turned out to be more
divergent than the genes encoding the capsid proteins
VP1 and VP2. The divergence was smallest within the
VP1 unique region. Also at the protein level the NS1
region was the most divergent—in contrast to most
animal parvoviruses—while the major capsid protein
VP2 showed a difference of only 1.1% compared to the Au
isolate. The similarity of the VP2 molecules might be
significant for host defense and diagnosis of B19 infec-
tions. Of note, Simian parvovirus (SPV), a B19-related
animal parvovirus, differed from the K71 human genotype
by more than 40%.
The B19 genome contains only one functionally active
promoter located at map unit 6. The p6 promoter is
trans-activated by the nonstructural protein NS1 and has
been shown to confer autonomous replication compe-
tence and erythroid specificity to adenoassociated virus
2 (4). Thus, the extreme tropism of B19 virus to erythroid
progenitor cells has been speculated to be, at least
partly, due to promoter strength influenced by cell-spe-
cific and cell cycle specific factors in combination with
the viral NS protein. In DNA sequence the p6 promoter
region has been considered highly conserved. In the
dermal K71 genotype, however, the noncoding region
upstream of the NS1 gene was the most divergent.
Within nucleotides 189–435, K71 differed from the Au
reference by 27% and from the V9 variant by 17%. Re-
gardless of its extensive sequence dissimilarity, the K71
promoter was shown here, by a standard luciferase gene
expression assay and the UT7/Epo-S1 cell line (22), to be
biologically active. Further studies are warranted con-
cerning the role of the NS1 protein and the p6 promoter
in tissue-type specificity and host-cell tropism of the K71
genotype.
In terms of sequence variation, DNA viruses have
been considered relatively stable. However, along with
the multitude of genotypes of the recently discovered
human circovirus TTV and with their extensive (30%)
intergenotype sequence variety (24), the present findings
show that even the structurally simplest DNA viruses are
far from monolithic. It is tempting to speculate that the
hitherto recognized human parvoviruses represent the
mere tip of the iceberg of a multitude of genotypes,
which by extensive divergence have escaped detection
by the amplification assays in current use.
Materials and Methods. Serum and tissue samples.
Skin biopsies were obtained with informed consent from
34 subjects: 20 had inflammatory B19-nonrelated derma-
tological lesions (group 1) and 14 were healthy members
of the hospital staff (group 2). Sera were obtained for
antibody testing. Circulating B19-IgG and IgM antibodies
FIG. 2. Phylogenetic tree of protein-coding regions of 14 B19 se-
quences and a Simian parvovirus (SPV) sequence. The K71 genotype is
represented by the LaLi isolate (GenBank No. AY044266). The B19
cluster includes eight blood-derived B19 isolates; Au (M13178), Wi
(M24682), Stu (Z68146), Rm (AB030694), N8 (AB030673), Mi (AB030693),
HV (AF162273), and a strain from an SLE patient (AF113323), as well as
the four synovial B19 sequences Kati1–4 (AF161223–AF161226). The
GenBank Accession No. for V9 is AX003421 and for SPV is SP26342.
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were measured, respectively, by in-house (25) and com-
mercial (Biotrin, Dublin, Ireland) enzyme immunoassays.
For further evidence of the time of B19 infection, epitope-
type specificity of B19-IgG was measured as described
(25, 26) in all B19-genopositive patients.
Synovial tissue and serum samples were obtained as
described (9) from subjects without B19-related disease.
For this study we randomly chose 16 synovial specimens
shown before to harbor the protein-coding region of the
B19 genome in full length (9, 17).
DNA Purification. DNA was purified by proteinase K
digestion with detergents (0.45% NP-40, 0.45% Tween,
2.5 mM MgCl2, 50 mM KCl, 1% gelatin in 10 mM Tris, pH
8.3) overnight at 55°C followed by 10 min incubation at
95°C to inactivate the enzyme (group 1), or by proteinase
K digestion followed by phenol/chloroform extraction and
ethanol precipitation (group 2 and synovial samples) as
described before (9).
PCRs and Sequencing. All the skin samples were first
screened by nested PCR for a conserved area of the VP1
gene (9). The B19 DNA-positive samples were studied
further with nested PCRs for two other B19 genomic
regions [NS1 and VP2 (17)]. The second-round products
were detected by agarose gel electrophoresis and
ethidium bromide staining, transferred onto nylon mem-
brane, and hybridized with respective digoxigenin-la-
beled probes prepared by PCR from viremic serum (17).
As most of the skin-derived amplicons from the NS1 and
VP2 PCRs did not hybridize or hybridized only weakly
(Fig. 1), they were sequenced, either directly or after
cloning (TA-cloning, Novagen Inc., Darmstadt, Germany),
to pick up possibly existing multiple genotypes. DNA
sequences were obtained with ABI PRISMa (Perkin-
Elmer, Foster City, CA) at the sequencing core facility of
the Haartman Institute, University of Helsinki, Finland. In
addition to the three B19 primer sets, others, prepared
according to the blood-derived reference sequence Au
or the current dermal B19 DNA, were used for amplifica-
tion and sequencing.
All the skin samples were studied further by nested
PCR specific for the new B19 genotype. The K71-specific
primers (within the NS1 gene) were as follows: outer
forward, 5-TTTACTGAAGACAAATGGAAGT; outer re-
verse, 5-CACTGGGACAGTTTTGGCAATA; inner forward,
5-AGTGGATTTCAATCAATATACA; inner reverse, 5-TCA-
TAATTTTGGCATAATAATAG. After 2 40 cycles and elec-
trophoresis, the PCR products were detected by ethidium
bromide staining.
Construction of B19 and K71 Promoter–Luciferase
Expression Plasmids. The B19-promoter region was am-
plified by PCR from viremic serum.NheI and XhoI restriction
sites were inserted at the ends of the PCR primers (forward:
5-TTTGCTAGCTAGTGGCACGTCAACCCC; primer: 5-
TTTCTCGAGGTTAGGATGTTAACAAGTAGTATAAATAC-
CTGTTAG). The K71-promoter region was amplified by PCR
from a pSTBlue-1 plasmid containing a fragment of K71
(nucleotides 144–1317). PCR was performed with a forward
primer specific for the pSTBlue-1 plasmid near its multiple
cloning site upstream from the K71 insert (5-ACGACTCAC-
TATAGGGAAAGCTCGG), and a K71-specific reverse primer
with XhoI restriction site inserted at the 5-end (5-
TTTCTCGAGGTTAGTAATTAAAAGTTAGTATAAATACCTG-
TTAAT). The purified PCR products were cloned into the
KpnI and XhoI sites of pGL3-Enhancer vector (Promega).
Another positive control was pGL3-Control, carrying
the luciferase gene under the SV40 promoter-enhancer.
The negative control was pGL3-Enhancer vector (lucif-
erase gene without promoter).
UT7/Epo-S1 Cells. UT7/Epo-S1 cells, shown to be
highly susceptible to B19 infection, were kindly donated
by Dr. Eiji Morita (22). The cells were seeded at
75,000/ml onto 12-well plates (1 ml/well) and were cul-
tured at 37°C in 5% CO2 in Iscoves modified Dulbecco’s
medium (IMDM) containing 10% FCS and 2 U erythro-
poietin (22).
DNA Transfection and Luciferase Assay. At day 1 of
exponential growth the cells (in duplicate wells) were
harvested by centrifugation and resuspended in 500 l
of growth media. Approximately 2 g of each plasmid
construct was transfected by electroporation, applying a
current of 250 mV and an electric field of 960 F with a
Gene Pulser Transfection Apparatus (Bio-Rad Laborato-
ries, Hercules, CA). Two days posttransfection the cells
were harvested, washed in phosphate-buffered saline
without Ca2 and Mg2, and lysed in 100 l of cell culture
lysis reagent (Promega) on ice for 30 min. A 20-l sample
of each lysate was mixed with 100 l luciferase assay
reagent (Promega), and RLU were measured with a lu-
minometer DCR-1 (MGM Instruments Inc., Hamden, CT)
for 10 s.
Phylogenetic Analysis. The protein-coding sequence
of one dermal isolate, LaLi, was aligned with 13 respec-
tive B19 sequences including 4 B19 DNA isolates per-
sisting in synovial membranes (17) and a Simian parvo-
virus sequence (20), all available in GenBank. Phyloge-
netic trees were reconstructed by the TreePuzzle
program using the maximum likelihood approach (27);
10,000 puzzling steps were applied using the HKY model
of substitution (28). DNA sequence divergences were
calculated by the Distances program (simple distances
with no corrections) in Wisconsin Package Version 10.2
(Genetics Computer Group GCG, Madison, WI).
Nucleotide Sequence Accession Numbers. The se-
quence data presented in this study can be found in
GenBank under Accession Nos. AY044266, AY044267,
and AY044268.
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